Recent Finacing
Recent Raise
Ophirex is a public benefit corporation developing varespladib, an oral and intravenous sPLA2 inhibitor for broad‑spectrum snakebite treatment intended for immediate out‑of‑hospital and clinical use.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Ophirex.
